ScaleReady Announces a G-Rex® Grant has been awarded to Seattle Children's Therapeutics
ScaleReady has awarded a $125,000 G-Rex Grant to Seattle Children's Therapeutics, a division of Seattle Children's Research Institute. The grant will support the integration of advanced technologies into their CAR-T cell platform, which has already utilized G-Rex bioreactors to manufacture cell therapy products for hundreds of clinical trial participants.
As part of the grant, Seattle Children's Therapeutics will explore fully closed G-Rex bioreactors and Bio-Techne's GMP-grade cytokines to optimize manufacturing for future trials. They will also receive early access to G-Rex product development and participate in evaluating new devices, including cell separation technology that isolates T-cells without expensive instrumentation.
This grant is part of ScaleReady's larger $20M initiative to advance cell and gene-modified cell therapy development and manufacturing, with individual grants worth up to $300,000.
ScaleReady ha assegnato una G-Rex Grant di 125.000 dollari a Seattle Children's Therapeutics, una divisione del Seattle Children's Research Institute. La sovvenzione supporterà l'integrazione di tecnologie avanzate nella loro piattaforma di cellule CAR-T, che ha già utilizzato bioreattori G-Rex per produrre prodotti di terapia cellulare per centinaia di partecipanti a studi clinici.
Come parte della sovvenzione, Seattle Children's Therapeutics esplorerà bioreattori G-Rex completamente chiusi e citochine di grado GMP di Bio-Techne per ottimizzare la produzione per i futuri trial. Riceveranno anche accesso anticipato allo sviluppo di prodotti G-Rex e parteciperanno alla valutazione di nuovi dispositivi, compresa la tecnologia di separazione cellulare che isola le T-cellule senza costose strumentazioni.
Questa sovvenzione fa parte dell'iniziativa più ampia di ScaleReady da 20 milioni di dollari per promuovere lo sviluppo e la produzione di terapie cellulari e terapie geniche modificate, con sovvenzioni individuali fino a 300.000 dollari.
ScaleReady ha otorgado una G-Rex Grant de 125,000 dólares a Seattle Children's Therapeutics, una división del Seattle Children's Research Institute. La subvención apoyará la integración de tecnologías avanzadas en su plataforma de células CAR-T, que ya ha utilizado bioreactores G-Rex para fabricar productos de terapia celular para cientos de participantes en ensayos clínicos.
Como parte de la subvención, Seattle Children's Therapeutics explorará bioreactores G-Rex completamente cerrados y citoquinas de grado GMP de Bio-Techne para optimizar la fabricación para futuros ensayos. También recibirán acceso anticipado al desarrollo de productos G-Rex y participarán en la evaluación de nuevos dispositivos, incluida la tecnología de separación celular que aísla las células T sin instrumentos costosos.
Esta subvención es parte de la iniciativa más amplia de ScaleReady de 20 millones de dólares para avanzar en el desarrollo y la fabricación de terapia celular y terapia génica modificada, con subvenciones individuales de hasta 300,000 dólares.
ScaleReady는 시애틀 아동 치료부(Sites Children’s Therapeutics)에게 125,000달러의 G-Rex Grant를 수여했습니다. 이는 시애틀 아동 연구소의 한 부서로, 이 보조금은 CAR-T 세포 플랫폼에 첨단 기술을 통합하는 것을 지원할 것입니다. 이미 G-Rex 생물 반응기를 이용하여 수백명의 임상 시험 참가자를 위한 세포 치료 제품을 제조했습니다.
보조금의 일환으로, 시애틀 아동 치료부는 향후 실험을 위한 제조 최적화를 위해 완전히 폐쇄된 G-Rex 생물 반응기와 Bio-Techne의 GMP 등급 사이토카인을 탐색할 것입니다. 그들은 또한 G-Rex 제품 개발에 대한 조기 액세스를 받고 비싼 장비 없이 T세포를 분리하는 기술을 포함하여 새로운 장치를 평가하는 데 참여하게 됩니다.
이 보조금은 세포 및 유전자 변형 세포 치료 개발 및 제조를 촉진하기 위한 ScaleReady의 2천만 달러 규모의 더 큰 계획의 일환으로, 개별 보조금은 최대 30만 달러에 달합니다.
ScaleReady a attribué une G-Rex Grant de 125 000 dollars à Seattle Children's Therapeutics, une division de l'Institut de recherche pour enfants de Seattle. La subvention soutiendra l'intégration de technologies avancées dans leur plateforme de cellules CAR-T, qui a déjà utilisé des bioréacteurs G-Rex pour fabriquer des produits de thérapie cellulaire pour des centaines de participants d'essais cliniques.
Dans le cadre de la subvention, Seattle Children's Therapeutics explorera des bioréacteurs G-Rex complètement fermés et des cytokines de qualité GMP de Bio-Techne afin d'optimiser la fabrication pour les futurs essais. Ils bénéficieront également d'un accès précoce au développement de produits G-Rex et participeront à l'évaluation de nouveaux dispositifs, y compris une technologie de séparation cellulaire qui isole les cellules T sans instrumentation coûteuse.
Cette subvention fait partie de l'initiative plus large de ScaleReady de 20 millions de dollars pour faire progresser le développement et la fabrication de thérapies cellulaires et de thérapies géniques modifiées, avec des subventions individuelles allant jusqu'à 300 000 dollars.
ScaleReady hat einen G-Rex Grant in Höhe von 125.000 US-Dollar an Seattle Children's Therapeutics, eine Abteilung des Seattle Children's Research Institute, vergeben. Der Zuschuss wird die Integration fortschrittlicher Technologien in ihre CAR-T-Zellen-Plattform unterstützen, die bereits G-Rex-Bioreaktoren zur Herstellung von Zelltherapieprodukten für Hunderte von Probanden klinischer Studien genutzt hat.
Im Rahmen des Zuschusses wird Seattle Children's Therapeutics vollständig geschlossene G-Rex-Bioreaktoren und die GMP-Qualität von Bio-Techne-Zytokinen erkunden, um die Herstellung für zukünftige Studien zu optimieren. Zudem erhalten sie frühzeitigen Zugang zur Produktentwicklung von G-Rex und werden an der Bewertung neuer Geräte teilnehmen, einschließlich der Zellseparationstechnologie, die T-Zellen ohne teure Instrumente isoliert.
Dieser Zuschuss ist Teil von ScaleReadys größerem 20-Millionen-Dollar-Initiative zur Förderung der Entwicklung und Herstellung von Zell- und genmodifizierten Zelltherapien, wobei einzelne Zuschüsse bis zu 300.000 Dollar betragen können.
- Grant provides $125,000 in funding for advanced technology integration
- Early access to product development pipeline and new G-Rex devices
- Access to exclusive support from ScaleReady's consortium partners
- None.
Insights
The
The grant's value extends beyond the monetary aspect - early access to G-Rex's product development pipeline and new cell separation technology could substantially reduce manufacturing costs and complexity. The ability to isolate T-cells within the bioreactor without expensive instrumentation is particularly noteworthy, as it addresses one of the major cost barriers in cell therapy production.
Seattle Children's track record of treating hundreds of clinical trial participants using G-Rex bioreactors validates the technology's reliability. Their early adopter status and extensive experience make them an ideal recipient to advance the platform's capabilities. This grant is part of a larger
This grant announcement carries strategic implications for Bio-Techne (TECH). While the
The partnership with Seattle Children's Therapeutics, a respected player in pediatric CAR-T development, provides valuable validation and real-world testing opportunities. Their feedback on new G-Rex devices and cell separation technology could accelerate product development and market adoption. The broader
For investors, this represents a calculated move to strengthen TECH's competitive position in the CGT manufacturing space, potentially leading to increased market penetration and recurring revenue streams from GMP-grade materials and equipment sales.
"This technology has been a core component of our CAR-T platform for many years, and we have manufactured cell therapy products for hundreds of clinical trial participants using G-Rex bioreactors," said Christopher Brown, Director of GMP Manufacturing at Seattle Children's Therapeutics.
"Seattle Children's was an early adopter of G-Rex and is comprised of world-class scientists, physicians, and engineers who bring hope to cancer patients," said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. "I'm happy to see them take advantage of our G-Rex Grant Program to further simplify the manufacture of their groundbreaking therapies."
As part of the G-Rex Grant, Seattle Children's Therapeutics will examine the full array of fully closed G-Rex bioreactors, as well as the broad range of Bio-Techne's GMP-grade cytokines, with the aim to optimize manufacturing for future CAR-T and other trials. In addition, under the G-Rex Grant, Seattle Children's Therapeutics will gain early access to the G-Rex product development pipeline and will participate in early evaluation of new G-Rex devices. This will also include assessment of G-Rex cell separation technology that isolates T-cells within a G-Rex bioreactor without need of expensive instrumentation.
ScaleReady's G-Rex Grant Program is a
For more information about the G-Rex® Grant Program, please contact info@scaleready.com.
About ScaleReady
ScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately
CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program, please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production.
Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-seattle-childrens-therapeutics-302345266.html
SOURCE Bio-Techne Corporation
FAQ
What is the value of the G-Rex Grant awarded to Seattle Children's Therapeutics?
How will Seattle Children's Therapeutics use the G-Rex Grant?
What is the total value of ScaleReady's G-Rex Grant Program?
What additional benefits does the G-Rex Grant provide to Seattle Children's Therapeutics?
